rope01 rope02

Pipeline

Our macrocyclic platform has fueled our pipeline of highly potent, proprietary kinase inhibitors that are structurally different from many existing kinase inhibitors and may address the key issues of emerging treatment resistance and toxicities that limit duration of treatment. We hold global development and commercialization rights to all of our drug candidates.

Candidate Selection

IND Enabling Studies

Phase 1

Phase 2

Phase 31

Upcoming
Milestones

(ROS1/TRKs/ALK)

Repotrectinib

(ROS1/TRKs/ALK)

Repotrectinib

ROS1+ advanced NSCLC in TKI-naïve patients

ROS1+ advanced NSCLC in TKI-pretreated patients

NTRK+ advanced solid tumors in TKI-naïve patients

NTRK+ advanced solid tumors in TKI-pretreated patients

TRIDENT-1
Registrational
cohorts

Current Phase

Phase 1

Upcoming Milestones

TRIDENT-1 Phase 1 enrollment ongoing2, Initiating registrational Phase 2 portion in 2H 2019

TRIDENT-1
Registrational
cohorts

TRIDENT-1 Phase 1 enrollment ongoing2, Initiating registrational Phase 2 portion in 2H 2019

ROS1+ or ALK+ non-NSCLC advanced solid tumors in TKI-naïve patients

Current Phase

Phase 1

Upcoming Milestones

Non-registrational cohort of TRIDENT-1

Non-registrational cohort of TRIDENT-1

Repotrectinib in pediatric advanced solid tumors

Current Phase

IND Enabling Studies

Upcoming Milestones

Initiating trial in 2H 2019

Initiating trial in 2H 2019

Repotrectinib + Tagrisso in EGFR mutated advanced NSCLC

Current Phase

IND Enabling Studies

Upcoming Milestones

Trial design in development

Trial design in development

(MET/CSF1R/SRC)

TPX-0022

(MET/CSF1R/SRC)

TPX-0022

Advanced solid tumor patients

Current Phase

Phase 1

Upcoming Milestones

Initiating trial in 2H 2019

Initiating trial in 2H 2019

(RET/SRC)3

TPX-0046

(RET/SRC)3

TPX-0046

Advanced solid tumor patients

Current Phase

IND Enabling Studies

Upcoming Milestones

Initiating trial in 2H 2019

Initiating trial in 2H 2019

ALK-INHIBITOR

ALK+ NSCLC

Upcoming Milestones

Candidate selection in 2019

Candidate selection in 2019

  1. Not required for Phase 2 registrational clinical trials
  2. Phase 1 Portion of TRIDENT-1 ongoing with anticipated data read outs within 2019
  3. Including NSCLC, thyroid, and other solid tumors with abnormal RET gene

Terms of Use | Copyright © 2019 Turning Point Therapeutics, Inc. | All Rights Reserved